Cargando…
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
PURPOSE: Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients with advanced cancers. The objectives of this analys...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870753/ https://www.ncbi.nlm.nih.gov/pubmed/33145616 http://dx.doi.org/10.1007/s00280-020-04184-z |